[go: up one dir, main page]

WO1992006976A1 - Derive de xanthine - Google Patents

Derive de xanthine Download PDF

Info

Publication number
WO1992006976A1
WO1992006976A1 PCT/JP1991/001420 JP9101420W WO9206976A1 WO 1992006976 A1 WO1992006976 A1 WO 1992006976A1 JP 9101420 W JP9101420 W JP 9101420W WO 9206976 A1 WO9206976 A1 WO 9206976A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
yield
ppm
brs
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1991/001420
Other languages
English (en)
Japanese (ja)
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Hiromi Nonaka
Nobuo Kosaka
Shunji Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to DE69130869T priority Critical patent/DE69130869T2/de
Priority to EP91917824A priority patent/EP0559893B1/fr
Publication of WO1992006976A1 publication Critical patent/WO1992006976A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Definitions

  • adenosine A 2 receptor antagonism (hereinafter, anti-2 will leave act) relates to novel 8-position mono-substituted Wisanchi emissions derivatives with.
  • New 8-position mono-substituted xanthine derivatives have anti-A 2 activity, asthma, has a therapeutic effect of osteoporosis.
  • Adenosine via the A 2 receptor are known to exhibit a bronchospasm action and bone resorption promoting action. Therefore adeno Thin A 2 receptor antagonists (hereinafter referred to as A 2 antagonist) is expected as a antiasthmatics, therapeutic agents for osteoporosis.
  • R 5 represents methyl or Echiru same or different
  • R 6 represents methyl
  • gamma represents hydrogen
  • Z 'is or off cycloalkenyl 3 4 represented by 5-Application Benefits main Tokishifu Weniru
  • Such compounds are disclosed as cerebral stimulants in Japanese Patent Publication No. 47-26516.
  • R 4 , R 5 and R 5 in the formula ( ⁇ ) represent methyl and Y 3 and ⁇ are hydrogen
  • Z 1 is phenyl (8-styrene) (Chem. Ber., 119, 1525, 1986) and Z 1 is pyridyl, quinolyl or methoxy.
  • a compound that is a substituted or unsubstituted benzothiazolyl (Chem. Abst., 60, 1741h, (1964)) is known, but its pharmacological action is described. No disclosure of the invention
  • the present invention relates to a compound of the formula (I)
  • R ′ and R 2 are the same or different and represent hydrogen, propyl, butyl or aryl
  • R 3 represents hydrogen or lower alkyl
  • Y 1 and Y 2 are the same or different.
  • Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a chelyl group.
  • the lower alkyl group is a straight-chain or branched-chain having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl Isopropyl, butyl, isobutyl, sec-butylyl, tert-butyl, pentyl, neopentyl, hexyl, etc., and the substituents of the phenyl group are the same or different and the number of substitution is 1 Examples of ⁇ 3 For example, lower alcohol, hydroxy, lower alkoxy, nodogen, amino, nitro, etc., and the alkyl moiety of lower alkyl and lower alkoxy are the same as the definition of lower alkyl described above. And haloge
  • the fluorine atom includes fluorine, chlorine, bromine and iodine atoms.
  • Pharmaceutically acceptable salts of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
  • the pharmacologically acceptable acid addition salts of compound (I) include inorganic acid salts such as hydrochloride, sulfate, phosphate, acetate, maleate, fumarate, and tartaric acid.
  • Organic salts such as salts and citrates; and pharmacologically acceptable metal salts include alkali metal salts such as sodium salt and potassium salt, and magnesium salts.
  • alkaline earth metal salts such as calcium and calcium salts, aluminum salts and zinc salts are also included.
  • ammonium salts include salts such as ammonium and tetramethylammonium.
  • organically acceptable organic amine addition salts addition salts such as morpholin and piperidine, and as pharmacologically acceptable amino acid addition salts, lysine and glycine And addition salts such as phenylalanine.
  • the compound (la) wherein R 3 is hydrogen can be obtained by the following reaction step.
  • Compound (V) can be obtained by reacting lacyl derivative (m) with carboxylic acid (IV) or its reactive derivative o
  • Compound ( ⁇ ) can be obtained according to a known method (for example, JP-A-59-42383).
  • the reactive derivative of the compound (IV) include acid halides such as acid chloride and acid bromide, and p-2-nitrophen.
  • Activated esters such as runiester and imido succinic acid ester, commercially available acid anhydrides and 1-ethyl 3- (3-dimethylaminopropyl) rubodimide, diisopropyl propyl carbodiimide, Examples thereof include acid anhydrides produced using carbodiimides such as dicyclohexylcarbodiimide, and mixed anhydrides with monoethylester carbonate and monoisobutyl carbonate.
  • a reactive derivative of the compound (IV) when used in this step, it can be carried out as follows according to a method commonly used in peptide chemistry.
  • compound (V) can be obtained by reacting compound (III) with a reactive derivative of compound (IV), preferably in the presence of an additive or a base.
  • reaction solvent examples include methylene chloride, macroform, methane hydrogen chloride such as ethane dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, and dimethylformamide. Til sulfoxide and ice, if necessary, are selected as appropriate.
  • 1-Hydroxybenzotriazole is used as an additive, and viridin, triethylamine, dimethylaminopyridine is used as a base. , N-methylmorpholine and the like.
  • the reaction is completed in 0.5 to 24 hours at -80 to 50 t. Further, the reactive derivative may be used without isolation after being formed in the reaction system.
  • the compound (Ia) can be obtained by reacting the compound (V) with a base (Method A) or a dehydrating agent (Method B) or by heating (Method C). Contains ⁇
  • alkali metal hydroxides such as sodium hydroxide and hydroxylating hydroxide are used as the base, and the reaction solvent is water, methanol, ethanol, or the like.
  • Lower alcohols, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide and the like are used alone or as a mixture.
  • the reaction is 0-180 t: and is completed in 10 minutes to 16 hours.
  • a thionyl halide such as thionyl chloride, or an oxyhalogenated phosphorus such as oxychlorinated chloride is used as a dehydrating agent.
  • Solvents inert to the reaction such as halogenated hydrocarbons such as dichloride tan, dimethylformamide, and dimethylsulfoxide, are used.
  • the response is from 0 to 180, and from 0.5 to: It ends in 12 hours.
  • a polar solvent such as dimethyl sulfoxide, dimethylformamide, Dow Thermo A (manufactured by Dow Chemical Company) or the like is used as a reaction solvent.
  • the reaction is completed at 50 to 200 in 10 minutes to 5 hours.
  • reaction solvent a mixed solvent of acetic acid and a lower alcohol such as methanol or ethanol is used. The reaction is completed in 0.5 to 12 hours at 20 to 100 t.
  • Compound (Ia) can be obtained by subjecting compound (W) to an oxidative toughening reaction in the presence of an oxidizing agent.
  • the oxidizing agent include oxygen, ferric chloride, cerium nitrate ammonium, and getyl azodicarboxylate.
  • the reaction solvent include methanol and phenol. Inactive in reactions such as lower-grade alcohols such as ethanol, halogenated hydrocarbons such as methylene chloride and black form, or aromatic hydrocarbons such as toluene, xylene, and nitrobenzene.
  • a solvent is used. The reaction is 0-180 and completes in 10 minutes to 12 hours.
  • Compound (lb) in which R 3 is lower alkyl in compound (I) can be obtained from compound (Ia) obtained in Production Method 1.
  • R 3 b represents a lower alkyl in the definition of R 3.
  • the compound (Ia) can be obtained by reacting the alkylating agent with the alkylating agent, if necessary, in the presence of a base.
  • suitable alkylating agents include alkyl halides such as methyl iodide, dialkyl sulfates such as dimethyl sulfate, and diazoalones such as diazomethane.
  • Examples of the base include alkali metal carbonates such as sodium carbonate and potassium carbonate, hydrogenated alkali metals such as sodium hydride, and sodium methoxide. And alkaline ethoxide Genuine lucoxide and the like. The reaction is from 0 to: 180 and ends in 0.5 to 24 hours.
  • the compound in which Z is imidazolyl is prepared in the same manner as in the above method, using the compound in which Z of the compound (la) is an imidazolyl group protected by a protecting group as a raw material. After the alkylation, the compound can be obtained by deprotection.
  • imidazolyl protecting groups include trityl, tosyl, benzyl, and benzyloxycarbonyl groups.
  • Intermediates and target compounds in the above-mentioned production methods are subjected to purification methods commonly used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, various types of mouth chromatography, etc. It can be purified.
  • the intermediate can also be subjected to the next reaction without purification.
  • compound (I) When it is desired to obtain a salt of compound (I), and when compound (I) is obtained in the form of a salt, it may be purified as it is.
  • compound (I) When compound (I) is obtained in a free form, compound (I) may be dissolved or suspended in an appropriate organic solvent and a salt may be formed by a method of adding an acid or a base. .
  • the compound (I) and a pharmacologically acceptable salt thereof may exist in the form of adducts with water or various solvents, and these adducts are also included in the present invention.
  • the present invention also includes all possible stereoisomers including the optical isomers and mixtures thereof. .
  • Table 1 shows specific examples of the compound (I).
  • Tris-HC ⁇ buffer PH7.7
  • Polytron homogenizer Kinematica
  • the suspension was centrifuged (50,000 xg for 10 minutes), and the obtained precipitate was re-suspended with the same amount of 50 mM Tris-HC ⁇ buffer, followed by the same centrifugation.
  • 50 mM Tris-HC ⁇ buffer solution was added and suspended so as to have a tissue concentration of lOOrag (wet weight) Zra2.
  • tissue suspension was incubated at 37 t for 30 minutes in the presence of adenosine kinase 0.02 unit Zmg tissue (Sigma). Then, the tissue suspension was centrifuged (50,000 xg, 10 minutes), and 50 mil Tris-HC ⁇ buffer solution was added to the obtained precipitate to a concentration of lOrag (wet weight) / mi. In addition, it was suspended.
  • a scintillator (BX-H; manufactured by Wako Pharmaceutical Co., Ltd.) was added, and the radioactivity on paper was measured with a liquid scintillation counter (Type 4530: manufactured by Packard).
  • the total binding amount is the 3 H-CHA binding radioactivity in the absence of the test compound.
  • the nonspecific binding, 10 iM N S - is a (L-2-full We two Louis Sopuro pills) adenosine (Sigma Co.) 3 H-CHA bound radioactivity content in the presence of.
  • the amount of binding in the presence of the drug is the amount of 3 H-CHA binding radioactivity in the presence of various concentrations of the test compound.
  • a final precipitate of striatum tissue was obtained by the same method as in the ⁇ receptor binding test described above. Add the final precipitate to a concentration of 5 (wet weight Zra?) In 50 mM Tris-HC ⁇ buffer (10 mM magnesium chloride, deinosindeminase 0.02 units). / mg tissue (Sigma was added and suspended.
  • the total amount of binding is the amount of 3 H- ⁇ -binding radioactivity in the absence of the test compound.
  • the non-specific binding amount is the amount of 3 H-NECA binding radioactivity in the presence of 100 M CPA.
  • the amount of binding in the presence of the drug refers to the amount of radioactivity bound to 3 H-NBCA in the presence of various concentrations of the test compound.
  • the vault of skull was aseptically removed from neonatal dd-mass 5-6 days after birth. After washing with calcium- and magnesium-free Dulbecco's modified phosphate-buffered saline (Gibco Oriental), the sections were split along the central suture line. Dulbecco's modified Eagle culture containing 15% equine serum and 2.5% calf fetal serum, heat-inactivated (56t, 20 minutes) of one half of the calvaria (Gibco Lental) 1.5 added me.
  • test compound control is DMSO only
  • reaction concentration 10_ reaction concentration 10_
  • Culture was performed for 96 hours by exchanging the culture solution at 48 hours under the conditions of 95% air, 5% carbon dioxide and a temperature of 37 t.
  • Calcium elution of bone or et al PTH are calcium ⁇ in c culture was measured amount of calcium in the culture fluid was collected 96 hours is Cal Shiumu C one test Wa co chromatography (OR (Manufactured by Kojun Pharmaceutical). The bone resorption rate was calculated according to the following formula, and the inhibitory effect was determined by Duncan's multiple comparison test for the control.
  • mice Five ddY male mice weighing 19 to 21 g were used per group. After the test compound and theophylline were orally administered to mice, they were placed in an acrylic gauge (26 x 45 x 25 cm) for measurement. 3 hours after administration The spontaneous momentum of the mouse was measured by Automex II (Columbus). Student t-test was performed between a drug-untreated control and a test compound or drug-administered group to determine an increase in spontaneous locomotor activity, and a minimum effective dose that showed a further significant difference was determined.
  • Theo off I Li down 2 0 4 test compounds with anti-A 2 acting according to the Table showed enhanced locomotor activity at doses of 1 or less to about 2 minutes Ri by Theo off I Li down.
  • Test compounds were orally administered to three male dd strain mice weighing 20 g and weighing 1 g per group.
  • Compound (I) shows potent anti-A 2 activity.
  • agents which compound (I) as an active ingredient is effective for various diseases you from hyperactivity of adeno Thin A 2 receptor.
  • Compound (I) or a pharmaceutically acceptable salt thereof can be used as it is or in various pharmaceutical forms.
  • the pharmaceutical composition of the present invention can be produced by mixing an effective amount of compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient with a pharmaceutically acceptable carrier. It is desirable that these pharmaceutical compositions are in a unit dosage form suitable for oral administration or administration by injection.
  • compositions in oral dosage form useful pharmacologically acceptable carriers can be used.
  • Oral liquid preparations such as suspensions and syrups, can be prepared from water, sugars such as sucrose, sorbitol, and fructoses, polyethylene glycol, propylene glycol and the like.
  • Glycols such as glycols, oils such as sesame oil, olive oil, soybean oil, preservatives such as p-hydroxybenzoic acid esters, st ⁇ -berry flavor, peppermint, etc. It can be manufactured using flavors and the like.
  • Powders, pills, capsules and tablets can be used as excipients such as lactose, glucose, sucrose, mannitol, disintegrants such as starch and sodium alginate, and stirrers.
  • Lubricants such as magnesium phosphate, talc, etc.
  • binders such as polyvinyl alcohol, hydric lip ⁇ pilcellulose and gelatin, surfactants such as fatty acid esters, and glycerin It can be manufactured using a plasticizer such as.
  • Tablets and capsules are the most useful unit oral dosage forms because of their ease of administration. When manufacturing tablets and capsules, an individual pharmaceutical carrier is used.
  • Injectable solutions can also be prepared using carriers consisting of distilled water, saline, glucose solutions, or a mixture of saline and sucrose solution.
  • the effective dose and frequency of administration of compound (I) or a pharmaceutically acceptable salt thereof will vary depending on the mode of administration, the age, weight, and condition of the patient, but is usually 0.01 to 50 mg per day. It is preferable to administer / kg in 3 to 4 divided doses.
  • Compound (I) can be administered by inhalation in the form of an aerosol, finely divided powder, or a nebulized solution.
  • the compound may be dissolved in a suitable pharmaceutically acceptable solvent such as ethyl alcohol or a combination of miscible solvents and mixed with a pharmaceutically acceptable propellant. It can be used as a mixture.
  • a suitable pharmaceutically acceptable solvent such as ethyl alcohol or a combination of miscible solvents. It can be used as a mixture.
  • Example 3 Using 2.28 g (6.79 mmol) of the compound 3 obtained in Example 3, the same procedure as in Example 2 was performed to obtain 1.37 g (yield 57%) of compound 4 as white crystals. .
  • Example 7 Using approximately 3.20 g (7.86 mmol) of the compound 7 obtained in Example 7, the procedure of Example 2 was repeated to give 2.8 g of compound 8 (yield as pale yellow crystals).
  • Example 5 was prepared using 5.0 g (22.1 mimol) of 1,3-dipropyl-5,6-diaminouuracil and 3.75 g (24.3 mimol) of 3- (2-phenyl) acrylic acid.
  • 6-amino 1,3-dipropyl-1-5- (3- (E)-(2-Chenyl) acyl) aminouracil (compound j) 7.33 g ( The yield was 92%) as amorphous crystals.
  • Example 2 Using 1.96 g (3.44 mmol) of a mixture of compound ⁇ and compound m, a crude product was obtained in the same manner as in Example 2. The crude product was dissolved in 50m ⁇ 2 of methanol, 1.5mj2 of 1N hydrochloric acid was added, and the mixture was stirred at 50t for 2 hours. The solution was concentrated to about half, the pH of the reaction solution was adjusted to 4, and the mixture was extracted six times with a black hole form. After the organic layers were mixed and dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure.
  • Example 5 was performed using 4.75 g (18.7 mimol) of 1,3-diptyl-5,6-diamino uracil and 4.90 g (20.6 mimol) of 3,4,5-trimethoxycinnamic acid.
  • a tablet consisting of the following composition is prepared by a conventional method.
  • a syrup having the following composition is prepared by a conventional method.
  • a forcepsel agent having the following composition is prepared by a conventional method.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Led Devices (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention se rapporte à un nouveau dérivé de xanthine représenté par la formule générale (I), qui a une action antagoniste sélective contre le récepteur d'adénosine, ainsi qu'à un sel pharmacologiquement acceptable de ce composé. Dans la formule (I), R1 et R2, qui peuvent être identiques ou différents, représentent chacun hydrogène, propyle, butyle ou allyle; R3 représente hydrogène ou alkyle inférieur; Y1 et Y2, qui peuvent être identiques ou différents entre eux, représentent chacun hydrogène ou méthyle; et Z représente phényle, pyridyle, imidazolyle, furyle ou thiényle substitué ou non.
PCT/JP1991/001420 1990-10-18 1991-10-17 Derive de xanthine Ceased WO1992006976A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE69130869T DE69130869T2 (de) 1990-10-18 1991-10-17 Xanthinderivate
EP91917824A EP0559893B1 (fr) 1990-10-18 1991-10-17 Derive de xanthine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2/280171 1990-10-18
JP28017190 1990-10-18

Publications (1)

Publication Number Publication Date
WO1992006976A1 true WO1992006976A1 (fr) 1992-04-30

Family

ID=17621294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1991/001420 Ceased WO1992006976A1 (fr) 1990-10-18 1991-10-17 Derive de xanthine

Country Status (6)

Country Link
EP (1) EP0559893B1 (fr)
AT (1) ATE176470T1 (fr)
CA (1) CA2094270C (fr)
DE (1) DE69130869T2 (fr)
ES (1) ES2130138T3 (fr)
WO (1) WO1992006976A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565377A1 (fr) * 1992-04-08 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Médicaments pour l'emploi dans le traitement de la maladie de Parkinson
WO1994003456A1 (fr) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Xanthine substituee asymetriquement ayant des proprietes antagonistes de l'adenosine
EP0590919A1 (fr) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Agents thérapeutiques pour la maladie de Parkinson
EP0607607A1 (fr) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Dérivés de la xanthine
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
ES2070087A1 (es) * 1993-08-13 1995-05-16 Pfizer Derivados de indol
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
EP0698607A4 (fr) * 1994-02-23 1996-03-27
US5543415A (en) * 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
WO1999035147A1 (fr) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
WO2005000313A1 (fr) * 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Agent antiepileptique
WO2005072739A1 (fr) * 2004-01-28 2005-08-11 Kyowa Hakko Kogyo Co., Ltd. Medicament contre la migraine
WO2007045705A2 (fr) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Composes servant a traiter la fibrillation auriculaire
EP2044940A2 (fr) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Procédé de traitement de patients ayant des troubles du mouvement
JP2010513353A (ja) * 2006-12-22 2010-04-30 シュバルツ ファルマ アクチェンゲゼルシャフト 選択的ａ２ａ受容体アンタゴニストとしての８−エチニルキサンチン誘導体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
CA2388176C (fr) * 1999-10-29 2007-09-25 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les troubles de l'alimentation
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
CA2670788A1 (fr) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. Antagonistes du recepteur d'adenosine a2a
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
CN110981876B (zh) * 2018-12-21 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204880A (ja) * 1989-10-20 1991-09-06 Kyowa Hakko Kogyo Co Ltd 縮合プリン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204880A (ja) * 1989-10-20 1991-09-06 Kyowa Hakko Kogyo Co Ltd 縮合プリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., Vol. 34, No. 4 (April 1991), R. H. ERICKSON et al. "1,3,8-Trisubstituted Xanthines. Effect of Substitution Pattern upon Adenosine Receptor A1/A2 Affinity", p. 1431-1435 particularly refer to page 1433. *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565377A1 (fr) * 1992-04-08 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Médicaments pour l'emploi dans le traitement de la maladie de Parkinson
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5587378A (en) * 1992-04-08 1996-12-24 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5543415A (en) * 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
WO1994003456A1 (fr) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Xanthine substituee asymetriquement ayant des proprietes antagonistes de l'adenosine
EP0590919A1 (fr) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Agents thérapeutiques pour la maladie de Parkinson
EP0607607A1 (fr) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Dérivés de la xanthine
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
US5861405A (en) * 1993-05-03 1999-01-19 The United States Of America As Represented By The Department Of Health And Human Services S-substituted 1,3,7-trialkyl-xanthine derivatives
ES2070087A1 (es) * 1993-08-13 1995-05-16 Pfizer Derivados de indol
EP0698607A4 (fr) * 1994-02-23 1996-03-27
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
WO1999035147A1 (fr) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
USRE39112E1 (en) * 1998-01-05 2006-05-30 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
EP2044940A2 (fr) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Procédé de traitement de patients ayant des troubles du mouvement
EP2260850A2 (fr) 2002-01-28 2010-12-15 Kyowa Hakko Kogyo Co., Ltd Antagonistes des récepteurs A2A pour utilisation dans le traitement des troubles du mouvement
EP2942082A2 (fr) 2002-01-28 2015-11-11 Kyowa Hakko Kogyo Co., Ltd Antagonistes des récepteurs A2A pour utilisation dans le traitement des troubles du mouvement
WO2005000313A1 (fr) * 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Agent antiepileptique
WO2005072739A1 (fr) * 2004-01-28 2005-08-11 Kyowa Hakko Kogyo Co., Ltd. Medicament contre la migraine
JPWO2005072739A1 (ja) * 2004-01-28 2007-09-13 協和醗酵工業株式会社 片頭痛の治療剤
JP4714024B2 (ja) * 2004-01-28 2011-06-29 協和発酵キリン株式会社 片頭痛の治療剤
EP2526949A1 (fr) 2004-01-28 2012-11-28 Kyowa Hakko Kirin Co., Ltd. Agents pour le traitement de la migraine
WO2007045705A2 (fr) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Composes servant a traiter la fibrillation auriculaire
JP2010513353A (ja) * 2006-12-22 2010-04-30 シュバルツ ファルマ アクチェンゲゼルシャフト 選択的ａ２ａ受容体アンタゴニストとしての８−エチニルキサンチン誘導体

Also Published As

Publication number Publication date
ATE176470T1 (de) 1999-02-15
EP0559893B1 (fr) 1999-02-03
DE69130869T2 (de) 1999-06-10
EP0559893A4 (en) 1994-07-06
EP0559893A1 (fr) 1993-09-15
CA2094270A1 (fr) 1992-04-19
ES2130138T3 (es) 1999-07-01
DE69130869D1 (en) 1999-03-18
CA2094270C (fr) 1997-01-21

Similar Documents

Publication Publication Date Title
WO1992006976A1 (fr) Derive de xanthine
US5670498A (en) 8-substituted styryl xanthine derivatives
US6821978B2 (en) Xanthine phosphodiesterase V inhibitors
US5525607A (en) Xanthine compounds
US7335655B2 (en) 8-heteroaryl xanthine adenosine A2B receptor antagonists
JP2613355B2 (ja) パーキンソン氏病治療剤
EP0698607B1 (fr) Derive de la xanthine
JPH06102662B2 (ja) キサンチン誘導体
JP4859666B2 (ja) Ａ１アデノシンレセプターアンタゴニスト
JPH09511496A (ja) 細胞内メッセンジャー
US20040034020A1 (en) Methods of treating periodontal disease
AU2001291022A1 (en) Xanthine phosphodiesterase v inhibitors
PL200551B1 (pl) Pochodne 3-(3-izopropylo-5-metylo-4H-1,2,4-triazol-4-ilo)-egzo-8-azabicyklo[3.2.1]oktanu, środek farmaceutyczny, zastosowanie tych pochodnych oraz środka farmaceutycznego i związki pośrednie
US5447933A (en) Xanthine derivatives
JP2613352B2 (ja) パーキンソン病治療剤
KR20060099513A (ko) 무스카린 수용체의 조정자로서의 페닐-피페라진 유도체
JP2988692B2 (ja) イミダゾキノロン誘導体
JP2843671B2 (ja) キサンチン誘導体
US5336769A (en) Xanthine derivatives
US5756735A (en) Xanthine derivatives
JP3115128B2 (ja) キサンチン誘導体
JPWO1992006976A1 (ja) キサンチン誘導体
JP3029870B2 (ja) キノリン誘導体
RU2333212C9 (ru) Производные 1-и 7-[омега-(бензгидрил-4-пиперазинил-1)алкил]-3-алкилсантинов, обладающие противогистамиинной и антиаллергической активностью
JPH06239862A (ja) キサンチン誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2094270

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991917824

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991917824

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991917824

Country of ref document: EP